Autism Researchers Are Beginning To Define Subtypes
Sometimes autism is defined in levels, other times with terms like 'mild' and 'profound,' and sometimes in terms of high and low support needs, but so far, no set of guidelines has accurately captured the complexity of range and nuance of autistic experience.
Redefining autism neurotypes in terms of subtypes could help overcome that quandary, although there's concern that it could further create 'boxes' that not everyone fits.
The definition of ASD is currently fairly broad. Diagnosis can involve checking the box on enough traits out of the long list as defined in the current edition of the DSM, which means that two people may both meet the criteria for diagnosis, yet have little in common.
In general, this involves at least some social struggles. However, that may range from one autistic person being completely nonverbal to another struggling with certain social cues or being extremely literal-minded. Some autistic people also learn heavy masking that can disguise these social struggles, though it can be extremely mentally and physically draining to do so.
Autism also involves some behavioral traits, but this, too, can vary, from one person's repetitive behaviors to another's sensory issues. It can involve highly restrictive routines or strong fixations on a special interest, and all of this may manifest differently depending on age, coping skills, and environment, among other factors.
This extreme diversity under one diagnostic term means that autistic people whose support needs are lower or whose traits are well-masked or otherwise less visible are often invalidated.
One study has examined the genetic profiles, traits, and development of more than 5,000 children, and the researchers are proposing four subtypes that would be employed to differentiate between the wide range of ways individuals experience and exhibit autism.
The four subtypes currently proposed would, according to Technology Networks, include Social and Behavioral Challenges; Mixed ASD with Developmental Delay; Moderate Challenges; and Broadly Affected.
Ideally, this would promote broader understanding among educators, employers, healthcare providers, and others that autism can involve less visible support needs, and that not all autistic individuals have challenges that are readily apparent in academics or communication.
It would also help families by helping to predict the types of struggles a child is most likely to face and hint at developmental arcs.
This subtype, the most common found in the study, represented about 37% of participants, and encompasses people whose autism results in a struggle to pick up on unspoken social cues, and those who may engage in repetitive behaviors like fidgeting, hair-pulling, or skin-picking.
These individuals may be later diagnosed because they may meet other developmental milestones within normal time frames. Some may begin reading early (hyperlexia), or they may start speaking at the latter end of the typical developmental time frame but immediately begin with complete sentences and unusual vocabulary. Others may seem to develop these skills in a typical way, and differences may not be noticeable until later.
Researchers think that some of these individuals may have genetic factors for autism, but that the factors may be 'activated' later in life, rather than presenting at birth.
These individuals may be more subject to social anxiety, depression, and other mental health struggles than their peers. They may overwork themselves with simply 'masking,' or hiding these autistic traits, consciously or subconsciously. For this reason, it could be very beneficial to identify the presence of these genes early to offer the necessary support.
Almost one in five kids in the study presented with this subtype. These individuals may be delayed in speech or in motor skills, and also show struggles with social interactions, as well as repetitive or compulsive behaviors.
Notably, researchers did not find that these individuals were more prone to anxiety or ADHD than their non-autistic peers.
Early diagnosis of this subtype could result in more tailored support and a better understanding of what the individual's capabilities could be, which could support parents in helping their child achieve within their abilities.
In examining genetic factors, researchers posited that this subtype seems to occur when the genes associated with autism are activated in utero, since it seems to show broad effects that may happen in early brain development.
About 1 in 3 study participants fall into this category. These individuals may show autistic traits, including social and behavioral struggles, at lower rates than some of their peers.
They are likely to reach developmental milestones on time and don't typically present with comorbidity of ADHD, anxiety, depression, or other mental health concerns.
Like those in the Social & Behavioral Challenges category, one key concern for this group may be that their symptoms and struggles can be easy to overlook (especially in families where a sibling has one of the subtypes that presents with developmental delays).
Here again, diagnosis is very valuable because it helps parents, educators, and others provide the child with the support they may not have otherwise recognized was needed.
While this may be the type of autism that people are most familiar with, it was the least common to appear in this study, affecting only about one in ten autistic kids.
In terms of genetic factors, researchers found it to have the highest incidence of de novo presentation — that means that it is more likely than other types to occur without a family history of autism. They also found it to have the highest incidence of unique genetic variations. They posit that these genetic mutations occur early in development, causing the highest level of developmental alterations.
These kids may present with more significant communication struggles, behavioral differences that significantly impact their lives, and significant developmental delays.
They also have higher rates of comorbidity with anxiety, depression, and other mood disorders, as well as intellectual disabilities.
Researchers merely propose these subtypes in one study. They have not, at this point, been added as official subtypes in the DSM, and your child's doctor or teacher may not, at this point, recognize them as distinct presentations.
The researchers in this same study also say that these four are only a beginning, and that further study could divide autism into more subtypes.
There are still reasons for hesitation about creating subtypes, including that this could be more exclusionary of individuals who don't perfectly fit one type or another but still need support. Any move forward should include providing support for all who need it, regardless of whether there's a specific label that fits an individual's presentation.
Also, though the study included more than 5,000 participants, it should be noted that it was U.S.-based and child-focused, so it also may not cover a full range of presentations based on different cultures, and into adulthood.
That said, the study does indicate the need for further investigation, and if the data is used to raise awareness for families and the general public, it could result in better understanding and support as needed for all autistic people.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
What you need to know before you call someone "Toxic"
We all know what it feels like to be around toxic energy. Toxic behavior isn't always obvious or intentional. Sometimes, it's survival mode in disguise. Other times, it's unhealed pain masked as control, criticism, or silence. In today's TikTok Therapy world, we throw around the term 'toxic' often, but rarely turn the lens inward. We're quick to call out ghosting, gaslighting, and manipulation in others, but what if the red flags are in the mirror? What happens when we pause and ask: Could I be showing up in ways that hurt the people I care about? This piece explores 7 subtle ways we might unknowingly bring toxic energy into our relationships and how awareness can lead to change. This isn't about shame, it's about courage. Let's gentle look inward before we point any fingers… Do you deflect blame or justify your mistakes? Accountability isn't about perfection, it's about owning your impact. If you often say things like 'Sorry you feel that way' or 'I wouldn't have done that if you hadn't…,' you might be dodging responsibility. If vulnerability was punished in your past, defensiveness may feel like self-protection. Try to shift: Replace blame with honest reflection. Shift from 'Why is this happening to me?' to 'What can I do next?' Do you correct, critique, or offer 'honest feedback' that no one asked for? There's a fine line between being real and being rude. If you regularly highlight flaws without balancing encouragement, it could be toxic. We often judge others where we feel most insecure ourselves. Try to shift: Offer the compassion you wish you'd received Swap unsolicited advice for active listening. Do you sulk, withdraw, or guilt-trip when disappointed? Manipulation isn't always calculated. Sometimes, it's a learned way to cope when direct communication seems unsafe. If expressing needs was ignored or punished, guilt might feel like the only no matter the underlying reason, yielding power over someone else isn't healthy. Try to shift: Practice stating your needs clearly. Map them out by yourself first. Know that you're allowed to want things, and to ask directly. Do you take 'no' personally? Are you often trying to change people's minds? Respecting boundaries is a critical relationship skill. If you find yourself pushing back when others set limits, it may be time to pause. If boundaries weren't modeled in childhood, they may feel like rejection now. Try to shift: Learn to recognize boundaries as safety that protects you and others too. Reflect on your own boundaries. Practice asking people to share their boundaries in times you are unclear. Do people feel uplifted or drained after being around you? Honest venting can be okay at times, but if you're often stuck in complaint mode, it can impact those around you. What examples do you have of raising the vibe and how does that compare to dampening the energy? Negativity can feel protective, like bracing for impact, but it also can inhibit connection. Try to shift: Notice and name small wins and joys. Ground your honesty in hope. Do you plan everything, lead everything, and struggle to let go? Control can feel like safety when you've experienced chaos or betrayal. Fear of abandonment and the unknown often fuel control. While these are understandable anxieties, without working on them the need for control can eave others feeling suffocated. Try to shift: Create a safe space to explore your fears of letting go Focus on building inner safety. Trust what's meant for you won't require force to stay. Do you ghost, shut down emotionally, or quietly build resentment? Sometimes toxicity is in what we don't do. Silence, avoidance, and passive withdrawal are all signs of disconnection. Avoidance often stems from fear of confrontation or not feeling safe to express emotion. Try this: Reflect on the difference between acceptance and avoidance Start small, you don't have to tackle your biggest problems first. Maybe you're wondering, 'Does this mean I'm toxic?' Not necessarily. Truth be told, if your toxicity was sky-high you likely wouldn't have made it this far into this article. If you did notice room for growth, excellent work! It's that awareness, that we often overlook, that sparks impactful change. Before you go please remember, no one is perfect, and being willing to look at the truth is meaningful work.
Yahoo
4 hours ago
- Yahoo
Takeda's oral narcolepsy drug shines in two Phase III trials
Takeda's oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their endpoints in patients with narcolepsy type 1 (NT1) after 12 weeks of treatment. The primary and secondary endpoints measured changes in wakefulness, excessive daytime sleepiness, cataplexy, ability to maintain attention, overall quality of life and daily life functions. These were all statistically significant and clinically meaningful improvements, achieving near normal ranges across the broad range of symptoms investigated. The drug also remained generally well-tolerated with a safety profile consistent with other oveporexton studies, with the most common adverse events (AEs) being insomnia, urinary urgency and frequency. No serious treatment-related adverse events were reported. Based on the study results, Takeda plans to submit a new drug application (NDA) to the US Food and Drug Administration (FDA) and other global regulators during the 2025 fiscal year. Oveporexton (TAK-861) is an investigational oral orexin receptor 2 (OX2R)-selective agonist. It is designed to address the core cause of NT1 by compensating for orexin deficiency, aiming to improve wakefulness and restore normal sleep-wake patterns. Orexin is a natural brain chemical that plays a crucial role in maintaining wakefulness and regulating the sleep-wake cycle. Takeda president Christophe Weber said: 'We are thrilled to reach this pivotal milestone for the oveporexton program. Oveporexton is a testament to Takeda's strength in discovering and developing a potential new class of medicines for difficult-to-treat diseases such as narcolepsy type 1.' Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study. In 2020, Jazz Pharmaceuticals' Xywav (calcium, magnesium, potassium, and sodium oxybates) was approved by the FDA and was the first approved new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years. Other treatment options for NT1 include trying to manage a regular sleeping pattern, as well as therapies, including stimulants such as Provigil (modafinil), Nuvigil (armodafinil), and Ritalin (methylphenidate) to promote wakefulness. Patients may also receive solriamfetol or pitolisant. To help with cataplexy attacks, either sodium oxybate or some antidepressants such as SSRIs [selective serotonin reuptake inhibitors] and SNRIs [serotonin-norepinephrine reuptake inhibitors] can be used to manage symptoms. If approved, GlobalData predicts sales of oveporexton will reach $1bn in 2030. GlobalData is the parent company of Clinical Trials Arena. "Takeda's oral narcolepsy drug shines in two Phase III trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio


Forbes
4 hours ago
- Forbes
Debunking The '54-Year Life Expectancy' Claim For Autistic People
Autistic people deserve better than a headline. Yet a widely circulated claim that autistic ... More individuals have an average life expectancy of just 54 years continues to echo across media outlets, high-impact journals, and even federal policy reports. Autistic people deserve better than a headline. Yet a widely circulated claim that autistic individuals have an average life expectancy of just 54 years continues to echo across media outlets, high-impact journals, and even federal policy reports. The source? A 2016 study by Hirvikoski et al. has been grossly misinterpreted and misapplied in both academic and public discourse. The reality is far more nuanced, and perpetuating this statistic is not only misleading but also harmful. According to Andy Shih, Chief Science Officer at Autism Speaks, "Data from credible previous studies suggests a shorter average life expectancy for autistic adults when compared to their peers of about 17 years. However, taking the limitations of those studies into account, we cannot say that this finding is generalizable across the world." What the Original Study Actually Said About Autistic People The Hirvikoski study did not find that all autistic people die at 54. In fact, fewer than 3% of the autistic cohort died during the study period, which renders it methodologically incorrect to extrapolate a mean age of death from such a small subset. "In the 2016 study by Hirvikoski, the authors extrapolated a mean age of death from a small subset," said Kimberly Idoko, MD, Esq., a board-certified neurologist and certified coach. "That's statistically inappropriate, and it creates a distorted picture that doesn't reflect the true life expectancy of autistic people." Gemma Williams, an academic researcher in the UK, echoed this sentiment. "Only around 3% of the autistic cohort died during the study, but only 0.91% of the non-autistic cohort died. We're still unclear on the percentage of autistic people in the wider population, but what's clear is that autistic people were more likely to have died from almost all types of medical conditions." Recent studies, such as this 2023 Lancet Regional Health study, provide a more accurate representation of the disparity, showing a life expectancy gap between autistic and non-autistic adults that is significant but not as extreme as the 54-year claim. The Real Consequences of Autistic Misrepresentation In a recent open-access study published in JAMA Network Open, researchers Lauren Bishop and Brittany ... More N. Hand analyzed the citations of the Hirvikoski study. Over 70% of citing authors misrepresented their findings. In a recent open-access study published in JAMA Network Open, researchers Dr. Lauren Bishop and Dr. Brittany N. Hand analyzed the citations of the Hirvikoski study. Over 70% of citing authors misrepresented their findings. "We expected to find that a sizable minority of articles misrepresented Hirvikoski et al's findings based on our anecdotal experiences as readers, reviewers, and editors," said Dr. Hand. "However, we were surprised to see how widespread these misrepresentations really were." This misinformation has not been contained within academia. "These misrepresentations have been perpetuated in really high-impact publications and news media," Hand explained. "They even appeared in reports to the U.S. Congress by the Department of Health and Human Services and a continuing education article from the CDC." The implications are vast. "Misrepresenting mortality statistics for autistic people can cause psychological distress for autistic individuals and their families," Hand added. "Our autistic adult advisory board frequently raises concerns about this narrative." This misinformation can also lead to insurance denials, distorted retirement planning, and worsened stigma. In her social work course, Dr. Bishop teaches this exact topic and notes that "most of my bachelor's- and master' s-level social work students make the very same interpretation mistakes that the citing authors in our study make." This isn't just about numbers; it's about how we shape perceptions and policies. Overshadowing Urgent Health Priorities This misplaced focus on a singular, misleading statistic diverts attention from the actual causes of health disparities. "Perhaps in part because of the misrepresentation of Hirvikoski et al.'s suicide findings," Bishop noted, "autism researchers have increasingly focused on suicide and suicidality instead of studying more prevalent causes of mortality, such as cardiovascular disease." Ms. Williams points out that in the UK, autistic individuals face significant healthcare barriers, including sensory challenges and communication issues that often prevent them from accessing timely care. "Many autistic people don't get past primary care with problems that quickly escalate," she said. "Add to that background stigma and reduced opportunities to participate in school, work, and social lives, and it paints a bleak picture." Shih agrees that more inclusive, long-term studies are needed. "Conducting studies like that led by Hirvikoski across every country would give us a more generalizable understanding of autism and aging," he said. "This would point to solutions and opportunities for improvement in these communities." A More Responsible Narrative For Autistic People So, how can we improve? First, by recognizing the responsibilities of researchers, reviewers, and editors. "Authors have a responsibility not to oversensationalize the titles of their research articles to the point of inaccuracy," said Dr. Hand. "Reviewers and editors must check for this." The term "premature mortality," used in the title of the Hirvikoski paper, is especially problematic. "There is not sufficient evidence from Hirvikoski et al., 2016 to support the idea that, at a population level, autistic people die prematurely," said Hand. Even researchers like Bishop and Hand have begun re-evaluating their own language use. "Now that we know better, we want to do better and start a conversation about it," Hand said. Dr. Bishop encourages a shift in focus: "Lots of autistic people age well and live long, healthy lives. Health and aging outcomes among autistic people are incredibly heterogeneous. We can do a lot at the individual, family, community, and systems levels to support folks to age and live well." Partnering with autistic people in the research process is also essential. "We need more information about autistic people's goals and priorities around aging," Hand emphasized. Bishop added that it's time to stop framing aging in autism as solely a problem. "Let's move toward studying healthy aging," she said. What Comes Next Shih emphasized that this is a global challenge: "Long-term, longitudinal studies are especially ... More critical to track autistic individuals across their lifespans. These must be fully inclusive, reflecting the full diversity of the autistic community." Studies of aging in autism are still in their infancy. "Many autism researchers refer to 'aging' autistic populations as those aging into adulthood or middle age," Hand said. "The narrative needs to expand to include aging into and through older adulthood." Bishop identified several critical, under-discussed issues: "Diagnosis in older adulthood, dementia, cardiovascular disease, reproductive health, and accommodating autistic older adults within the healthcare system all need more attention." Shih emphasized that this is a global challenge: "Long-term, longitudinal studies are especially critical to track autistic individuals across their lifespans. These must be fully inclusive, reflecting the full diversity of the autistic community." The myth of the 54-year life expectancy for autistic people has persisted long enough. "It's more important to reckon with reality than let small numbers in one study steer public thinking," said Williams. Responsible communication isn't just good science, it's good humanity.